Evidence map›Paper›PMID 30995439›Full record

ArticleMetabolism: clinical and experimental2019

Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration.

Louis Ma, Dick C Chan, Esther M M Ooi, P Hugh R Barrett, Gerald F Watts

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Metabolism: clinical and experimental, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04613167 naunknown statusstarted 2020, after this paper: background citation

Genetic, Biochemical and Functional Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment Options

Ran2020Enrolled70Registered outcomes3Posted comparisons0ConditionsAcute Coronary Syndrome, Genetic Polymorphisms, Inflammation, LipoproteinemiaArmsAlirocumab, Control group, Evolocumab
PMID 30838555PMID 31061262PMID 32453609PMID 19124843PMID 19622820PMID 20032323PMID 23594558PMID 25120086PMID 26002446PMID 26428312PMID 26637278PMID 28183512other papers from this trial
Open the trial in the graph
NCT04993664 nawithdrawnnot on this mapstarted 2021, after this paper: background citation

Influence of Pelacarsen on Arterial Wall Properties and Risk Factors in Patients After Myocardial Infarction With High Lp(a) Values

TypeinterventionalSponsorUniversity Medical Centre LjubljanaRan2021 to 2022Enrolled0ConditionsAcute Coronary Syndrome, Lipoproteinemia, Inflammation, Genetic PolymorphismsArmsPelacarsen (TQJ230), Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Louis MaSchool of Biomedical Sciences, University of Western Australia, Perth, Australia; School of Medicine, University of Western Australia, Perth, Australia.
Dick C ChanSchool of Biomedical Sciences, University of Western Australia, Perth, Australia; School of Medicine, University of Western Australia, Perth, Australia.
Esther M M OoiSchool of Biomedical Sciences, University of Western Australia, Perth, Australia.
P Hugh R BarrettFaculty of Medicine and Health, University of New England, Armidale, Australia.
Gerald F WattsSchool of Medicine, University of Western Australia, Perth, Australia; Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Australia. Electronic address: gerald.watts@uwa.edu.au.
University of Western Australia · AURoyal Perth Hospital · AUUniversity of New England · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextLipoprotein(a) [Lp(a)] is a highly atherogenic lipoprotein characterized by apolipoprotein(a) [apo(a)] covalently bounded to apoB-100 (apoB). However, the metabolism of apo(a) and apoB within plasma Lp(a) particles in patients on statins remains unclear.

methodsThe kinetics of Lp(a)-apo(a) and Lp(a)-apoB were determined in 20 patients with elevated Lp(a) (≥0.8 g/L; n = 10) and normal Lp(a) (≤0.3 g/L; n = 10) using stable isotope techniques and compartmental modeling. Plasma apo(a) concentration was measured using liquid chromatography-mass spectrometry. All patients were on statin therapy and were studied in the fasting state.

resultsThe fractional catabolic rate (FCR) of Lp(a)-apo(a) was not significantly different from that of Lp(a)-apoB in statin-treated patients with elevated or normal Lp(a) (P > 0.05 in both). Lp(a)-apo(a) FCR was significantly correlated with Lp(a)-apoB in patients with elevated and normal Lp(a) concentrations (r = 0.970 and r = 0.979, respectively; all P < 0.001) with Lin's concordance test showing substantial agreement between the FCRs of Lp(a)-apo(a) and Lp(a)-apoB in patients with elevated and normal Lp(a) concentrations (r

conclusionOur data indicate that the apo(a) and apoB proteins within Lp(a) particles have similar FCR and are therefore tightly coupled as an Lp(a) holoparticle in statin-treated patients with elevated and normal Lp(a) concentrations.

Indexed as

AdolescentAdultAgedApolipoprotein B-100Apolipoproteins AFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasKineticsLipoprotein(a)MaleMiddle AgedYoung AdultAPOB protein, humanApolipoprotein B-100Apolipoproteins AHydroxymethylglutaryl-CoA Reductase InhibitorsLipoprotein(a)

Identifiers

PMID30995439
OpenAlexW2935757500

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.